Regenerative Medicine Co., Ltd.
The Regenerative Medicine Leader

Regenerative Medicine Co., Ltd. (ReGenMed) has been a leader in regenerative healthcare for the last two decades, guiding physicians and medical clinics through advancements in biomedicine. The company’s sustained success stems from its keen observation of industry trends and its proactive adoption of new technologies.

ReGenMed’s growth trajectory in the field of regenerative medicine is driven by its leadership team. The president, Narin Apichairuk, and director, Brian Dardzinski, bring substantial experience in this field. Before joining ReGenMed, the duo played pivotal roles at an innovative stem cell company that was the first company in the world to offer stem cell treatments commercially. The company treated cardiomyopathy using blood-derived stem cells. The knowledge gained from this experience continues to shape ReGenMed’s advancements in the industry.

Reflecting on this journey, Apichairuk states, “Our extensive involvement in the regenerative medicine field from its nascent stages has been instrumental in shaping the path for ReGenMed. We have witnessed the industry’s evolution firsthand, and leveraging this unique perspective has been pivotal in taking our company to the next stage.” Dardzinski adds, “By pushing boundaries, ReGenMed pioneers new treatment modalities and methodologies, positioning the company as a trailblazer in the ever-evolving landscape of regenerative medicine and integrative healthcare.”

Beacon of Innovation and Excellence in Regenerative Medicine

From the outset, one of ReGenMed’s core goals was to offer products at a more affordable price point, ensuring that transformative treatments could reach a broader demographic and help more people.

The company’s approach, however, is not just focused on its products’ sales; it is distinguished by its consultative nature. ReGenMed educates its clientele, helping them address the difficulty in discerning the latest biomedicine advancements in the market.

ReGeMed organizes training events and conferences and provides comprehensive education to doctors and clinics. This equips their partners with the essential knowledge and tools for making well-informed decisions.

The other aspect underscores the importance of rigorous clinical research. This includes helping healthcare providers with thorough testing and analysis of ReGenMed’s products and those of its competitors. This scientific scrutiny ensures that ReGenMed’s offerings are consistently validated for their safety and efficacy.

Their evidence-based approach has helped the company establish a solid and respected reputation within the medical community.

Advancing Health and Longevity

ReGenMed’s industry-leading InfiNADi NAD+ showcases the company’s expertise in improving health and longevity.

InfiNADi NAD+ taps into the therapeutic benefits of nicotinamide adenine dinucleotide, a crucial coenzyme for DNA repair, cell maintenance and healthy cellular metabolism. Playing a critical role in mitochondrial function, NAD+ is vital for energy production and combating the mechanisms of age related decline.

infiNADi NAD+ addresses the natural decline in NAD+ levels as one ages. The product effectively boosts and sustains NAD+ levels in the body, making its anti-aging and performance-enhancing benefits easily accessible to those seeking to improve their health and longevity. The efficacy and safety of InfiNADi NAD+ has played a pivotal role in its widespread acceptance and adoption within the medical community. Extensive research and clinical trials have demonstrated the product’s ability to effectively rejuvenate cells and mitigate the effects of aging, instilling confidence among healthcare professionals and patients alike.

ReGenMed prioritizes evidence-based practices and ensures that all claims regarding the product’s efficacy are backed by rigorous scientific research and data. This commitment to transparency fosters trust among healthcare professionals, reinforcing InfiNADi NAD+’s premium status and explaining why the product is the #1 most used NAD+ globally.

Furthermore, ReGenMed’s dedication to providing comprehensive support and education to partner clinics and doctors has been instrumental in driving the success of InfiNADi NAD+. By offering ongoing training, the company enables doctors to confidentially educate end-users, empowering patients to make informed decisions about their health and treatment options.

Facilitating Quicker Access to Latest Medical Technologies

The efficacy of infaNADi NAD+ was notably demonstrated in a 75-year-old Parkinson’s patient. After undergoing a personalized therapy regimen, and high-dose infiNADi NAD+, the patient showed significant improvement within five months, regaining independent mobility.


ReGenMed’s objective is to democratize its healthcare solutions. Initially manufactured in European laboratories, the product faced market constraints due to high overhead costs despite strong demand. To overcome this, the company relocated production to cost-effective APAC regions, enabling it to maintain high-quality standards while significantly reducing manufacturing expenses.


This cost reduction is particularly impactful in the Asian market, where insurance coverage is less developed. As a result, ReGenMed can offer its advanced products to a broader audience at more competitive prices.

Bringing the Transformative Benefits of Regenerative Medicine

Apart from its flagship product, InfiNADi NAD+, ReGenMed has other innovative offerings that have garnered attention and acclaim within the industry.

Dardzinski states, “Innovation is at the forefront of our approach, with a dedicated focus on exploring new possibilities and pushing the boundaries of scientific advancements.”

The company’s REVIVE Exosomes represent cutting-edge cell-free technology aimed at rejuvenating cellular function and promoting tissue repair.

These advanced exosome-based therapies have shown promising results in regenerative medicine, offering a non-invasive approach to address a wide range of medical conditions. Another standout product in ReGenMed’s portfolio is REPLAY Placenta Extract, featuring a first-of-a-kind breakthrough by offering gender-specific formulations tailored for male and female users. This pioneering technology harnesses the regenerative power of placental extracts. ReGenMed’s newly launched product, Immunax, is an advanced immune enhancer designed to bolster the body’s natural defenses. With a unique blend of potent ingredients, Immunax offers comprehensive immune support, particularly in today’s environment, where maintaining optimal immune health is paramount.

Looking ahead to 2024, the company plans to aggressively expand into the US and European markets. In addition, the company is excited to announce its venture into the B2C market with a line of advanced cosmeceuticals inspired by the REPLAY product line. These cosmeceuticals will leverage the latest advancements in regenerative skincare.

Additionally, based on the success of InfiNADi NAD+, the company will introduce sublingual NAD+ supplements, offering consumers a convenient and effective way to support cellular health and overall well-being. These products will further expand reach and impact, bringing transformative benefits to a broader audience.

Leader in Regenerative Medicine
ReGenMed’s commitment to health and well-being is exemplified by its First Access program, which offers patients early access to cutting-edge regenerative therapies. This program underscores the company’s dedication to innovation and its mission to enhance the health and well-being of those in need.

ReGenMed is not just advancing the frontiers of regenerative medicine; it is ensuring patient benefit promptly from the latest healthcare innovations, making a transformative mark on their lives and the medical industry. “By integrating precision medicine with advanced integrative therapies, ReGenMed is positioned as a leader in delivering transformative healthcare experiences,” says Apichairuk. He adds, “Our success is measured by the tangible and positive impacts we have on patient lives.”

Its emphasis on the human dimension of healthcare has cultivated strong partnerships with healthcare professionals who value the company’s mission to make a meaningful difference. Beyond financial considerations, ReGenMed’s dedication to patient-centric care and altruistic values has solidified its reputation as a trusted and respected ally in the field of regenerative medicine.